MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Last trade$13.68
Day change+$0.125 (+0.92%)
Day range$13.22 – $13.94
Volume85,344
Market cap$195M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$194.99M
Price / earnings
—
Price / book
8.31×
Price / sales
348.19×
EV / sales
272.3×
EV / EBITDA
-6.93×
Profitability
Earnings per share
-$1.74
Return on assets
-47.69%
Return on equity
-106.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.68×
Quick ratio
9.35×
Cash ratio
8.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MDWD, quarterly periods
Line item
Q4 FY2015 Dec 31, 2015
Q3 FY2015 Sep 30, 2015
Q1 FY2015 Mar 31, 2015
Q4 FY2014 Dec 31, 2014
Q3 FY2014 Sep 30, 2014
Q2 FY2014 Jun 30, 2014
Q1 FY2014 Mar 31, 2014
Revenue
$267K
$102K
$67K
$124K
$46K
$39K
$50K
Cost of revenue
$689K
$824K
$175K
$1.14M
$750K
$723K
$170K
Gross profit
-$422K
-$722K
-$108K
-$1.02M
-$704K
-$684K
-$120K
Selling, general and administrative
$4.11M
$2.81M
$2.96M
$4.07M
$3.49M
$3.11M
$2.88M
Research and development
$2.29M
$836K
$1.4M
$1.5M
$1.03M
$1.36M
$1.47M
Total operating expenses
$6.41M
$3.64M
$4.36M
$5.57M
$4.52M
$4.47M
$4.35M
Operating income
-$6.83M
-$4.36M
-$4.47M
-$6.59M
-$5.22M
-$5.15M
-$4.47M
Interest expense
-$415K
-$344K
-$1.6M
-$562K
-$532K
-$936K
-$791K
Income before taxes
-$7.78M
-$3.77M
-$5.99M
-$7.09M
-$5.02M
-$6.03M
-$735K
Income taxes
—
—
—
—
—
—
—
Net income
-$7.78M
-$3.77M
-$6.41M
-$7.09M
-$5.02M
-$6.02M
-$749K
Net income attributable to common shareholders
-$7.78M
-$3.77M
-$6.41M
-$7.09M
-$5.02M
-$6.02M
-$749K
EBITDA
-$6.83M
-$4.24M
-$4.35M
-$6.59M
-$5.07M
-$5.01M
-$4.35M
Basic earnings per share
-$2.52
-$1.19
-$2.10
-$2.38
-$1.68
-$1.96
-$0.35
Diluted earnings per share
-$2.52
-$1.19
-$2.10
-$2.38
-$1.68
-$1.96
-$0.35
Recent news
Company coverage with links to the original publishers.
MediWound (MDWD) reported a quarterly loss of $0.65 per share, slightly beating the consensus estimate of $0.66 loss, but significantly missed revenue expectations with $3.57 million versus the consensus estimate, representing a 53.15% miss. The company's stock has underperformed the market by 25.1% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market in the near term.
MediWound reported Q3 2026 revenue of $3.6 million, down from $5.4 million year-over-year, primarily due to lower development services revenue related to uncertain U.S. government funding discussions. The company's EscharEx Phase III VALUE trial remains on track for interim assessment and enrollment completion by end of Q1 2027. NexoBrid achieved its strongest quarter since launch with record ordering centers and repeat orders. MediWound strengthened its balance sheet with $17.25 million from a public offering and received an additional $3.3 million in non-dilutive DoD funding for battlefield burn care development.
MediWound (MDWD) shares rose 6.1% following strong commercial performance of its NexoBrid therapy for burn treatment, with record quarterly revenue and growing hospital adoption. The company expects quarterly losses of $0.66 per share but projects 40.4% revenue growth. However, unchanged earnings estimates suggest caution about sustained momentum.
MediWound Ltd. announced it will release Q1 2026 financial results on May 27, 2026, followed by a conference call at 8:30 a.m. ET. The company will discuss results and provide a corporate update on its enzymatic therapeutics pipeline, including FDA-approved NexoBrid® for burn treatment and late-stage EscharEx® for chronic wound debridement.
MediWound announced multiple presentations of new preclinical and clinical data for EscharEx at three major wound care conferences in April and May 2026. The data demonstrates EscharEx's superior debridement mechanism compared to SANTYL, improved scar outcomes, and supports the ongoing Phase III VALUE trial in venous leg ulcers, with planned expansion into diabetic foot ulcers and pressure ulcers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.